1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,550 | 8,650 | 05.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | AgomAb Therapeutics NV: Agomab Announces Results of Annual General Meeting | 89 | GlobeNewswire (Europe) | Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual... ► Artikel lesen | |
| 24.04. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.04. | AgomAb Therapeutics NV: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook | 228 | GlobeNewswire (Europe) | -- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --... ► Artikel lesen | |
| 23.04. | Agomab Therapeutics NV - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 26.03. | Agomab receives U.S. patent for lung fibrosis drug candidate | 3 | Investing.com | ||
| 26.03. | AgomAb Therapeutics N.V.: Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis | 140 | GlobeNewswire (Europe) | Antwerp, Belgium, March 26, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent... ► Artikel lesen | |
| 11.03. | Agomab Therapeutics NV - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.03. | Morgan Stanley initiates Agomab Therapeutics stock with overweight rating | 5 | Investing.com | ||
| 03.03. | Morgan Stanley stuft Agomab Therapeutics mit "Overweight" ein und sieht 73 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 03.03. | JPMorgan initiates Agomab Therapeutics stock at Overweight | 2 | Investing.com | ||
| 03.03. | JPMorgan startet Coverage für Agomab Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| 09.02. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 09.02. | AgomAb Therapeutics N.V.: Agomab Announces Closing of Initial Public Offering | 491 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| 06.02. | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| 06.02. | Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut | 1 | Reuters | ||
| 06.02. | NASDAQ-Debüt: Aktie von Agomab Therapeutics startet unter Ausgabepreis | 1 | Investing.com Deutsch | ||
| 06.02. | Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million | 3 | Renaissance Capital | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,00 % bei einem Aktienkurs von 9,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.